ADAMTS13 factor deficiency in severe COVID-19 may not be immune mediated – report from a pilot study
- 16 November 2022
- journal article
- research article
- Published by IOS Press in Clinical Hemorheology and Microcirculation
- Vol. 82 (2), 193-198
- https://doi.org/10.3233/ch-221514
Abstract
BACKGROUND: The assessment of ADAMTS13 factor activity and inhibitor levels was conducted in severe COVID-19 patients as an observational study. RESULTS: A total of 14 patients were included and the average ADAMTS13 activity level at the time of admiKeywords
This publication has 17 references indexed in Scilit:
- Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysisClinical Hemorheology and Microcirculation, 2021
- A case of thrombotic thrombocytopenic purpura associated with COVID-19Journal of Thrombosis and Thrombolysis, 2021
- COVID-19 presenting as thrombotic thrombocytopenic purpura (TTP)BMJ Case Reports, 2020
- ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpuraJournal of Thrombosis and Haemostasis, 2020
- Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a caseThrombosis Research, 2020
- The unique characteristics of COVID-19 coagulopathyCritical Care, 2020
- Contrast enhanced ultrasonography (CEUS) to detect abdominal microcirculatory disorders in severe cases of COVID-19 infection: First experienceClinical Hemorheology and Microcirculation, 2020
- Coagulation abnormalities and thrombosis in patients with COVID-19The Lancet Haematology, 2020
- Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasisJournal of Thrombosis and Haemostasis, 2020
- Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathiesBritish Journal of Haematology, 2012